Fractionated high-dose-rate brachytherapy in the management of uterine cervical cancer

Hee Chul Park, Chang Ok Suh, Gwi Eon Kim

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


It is well known that intracavitary radiotherapy (ICR), either alone or in combination with external-beam radiotherapy (EBRT) is an essential component of the radiation treatment of uterine cervical cancer. Although low-dose-rate (LDR) brachytherapy has been successfully applied to the management of such patients, several radiation oncologists have experience of using high-dose-rate (HDR) brachytherapy with promising clinical results over the past 4 decades. However, there has been a considerable reluctance by radiation oncologists and gynecologists in North America to employ the HDR remote afterloading technique instead of the more firmly established LDR treatment modality. In contrast, the HDR-ICR system is rapidly gaining acceptance in Korea since the introduction of the Ralstron, remotely controlled afterloading system using HDR Co-60 sources, at the Yonsei Cancer Center in 1979. According to brachytherapy statistics reported by the Korean Society of Therapeutic Radiology and Oncology, in 1997, brachytherapy was performed upon 1,758 Korean patients with uterine cervical cancer, of whom approximately 83% received HDR brachytherapy. In this review, we present our experiences of HDR-ICR for the treatment of uterine cervical cancer. In addition, we discuss the controversial points, which are raised by those considering the use of HDR-ICR for uterine cervical cancer; these issues include physical and radiobiological considerations, and the prospect of future technical improvements.

Original languageEnglish
Pages (from-to)737-748
Number of pages12
JournalYonsei medical journal
Issue number6
Publication statusPublished - 2002 Dec

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Fractionated high-dose-rate brachytherapy in the management of uterine cervical cancer'. Together they form a unique fingerprint.

Cite this